

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Redefining typhoid diagnosis: what would an improved test need to look like?

Richard Mather^{1,2}, Heidi Hopkins², Christopher M. Parry^{3,4}, Sabine Dittrich^{1,5}

1. FIND, Malaria and Fever Program, Geneva, Switzerland
2. London School of Hygiene and Tropical Medicine, London, UK
3. Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
4. School of Tropical Medicine and Global Health, Nagasaki University, Japan
5. Nuffield Department of Medicine, University of Oxford, Oxford, UK

24 INTRODUCTION

25 Typhoid fever (typhoid) is an enteric bacterial infection caused by *Salmonella enterica* serovar Typhi
26 (*Salmonella* Typhi; *S. Typhi*). It is one of the most common bacterial causes of acute febrile illness in
27 the developing world,[1] with an estimated 10.9 million new cases worldwide and 116.8 thousand
28 deaths in 2017.[2,3] Paratyphoid fever caused by *Salmonella enterica* serovars Paratyphi A, B and C
29 (*S. Paratyphi*) results in a disease that can have an identical clinical syndrome to typhoid fever,[4] but
30 is often less severe.[5] Typhoid fever is most common in South Asia and sub-Saharan Africa, with
31 children predominantly affected. Like many febrile illnesses, typhoid presents with non-specific
32 symptoms and signs, especially in its early stages. In routine healthcare settings in low- and middle-
33 income countries (LMIC), typhoid fever is commonly suspected and treated empirically with
34 antibiotics.[6] This overuse of antibiotics creates a selective pressure for the development of
35 antimicrobial resistance (AMR),[7] that has resulted in the emergence and spread of typhoid strains
36 that are resistant to all first-line antibiotics.[8] Similarly, the low specificity of current rapid
37 diagnostic tests (RDTs) can lead to an over diagnosis of typhoid fever that may result in the overuse
38 of antibiotics and delay the proper treatment for underlying conditions. For example, the use of the
39 Widal test during an outbreak of acute febrile illness in Nepal led to misdiagnosis of typhoid which
40 delayed the appropriate treatment of the causative agent (scrub typhus), resulting in dozens of
41 deaths.[9] The potential harms of current typhoid RDTs are compounded by the fact they are widely
42 available, cheap and easy to use.[10]

43

44 Various aspects of *S. Typhi* biology make diagnosis by standard laboratory methods challenging. *S.*
45 *Typhi* is able to bypass the gastrointestinal mucosal barrier that restricts other enteric bacteria and can
46 evade the typical innate immune responses with limited activation of inflammatory pathways.[11] *S.*
47 *Typhi* infection begins with invasion of the mucosa of the terminal ileum, and the organism is thought
48 to only be transiently present in the blood before dissemination throughout the reticuloendothelial
49 system into the bone marrow, liver and spleen.[12] The bacterial load in peripheral blood peaks in the
50 first week of illness,[13] but is still very low with a median of 0.1-1.0 colony forming units (CFU)/mL
51 in symptomatic patients.[14] This concentration is difficult to detect by blood culture or PCR,
52 resulting in lower sensitivity for these diagnostic tests. *S. Typhi* is a member of the Enterobacteriaceae
53 family, and antibodies that have been produced in response to prior infections with other
54 Enterobacteriaceae tend to cross-react with *S. Typhi*,[12] due to significant conservation of surface
55 antigens. This cross-reactivity lowers the specificity of antibody-based diagnostic assays that
56 otherwise are well suited for a simple, rapid and inexpensive test format. Compounding the challenge,
57 the muted immune response that occurs through expression of the Vi capsular polysaccharide[12] may
58 further hinder the utility of serological tests for typhoid diagnosis.

59

60 In clinical settings supported by a microbiology laboratory, invasive typhoid infection is confirmed
61 through isolation of *S. Typhi* from blood cultures, but this is relatively expensive, can take >48 hours,
62 has low sensitivity, and requires laboratory infrastructure and trained staff that are not commonly
63 available in LMIC where typhoid is most prevalent.[15] Bone marrow cultures have high sensitivity
64 for detection of *S. Typhi* but are not routinely used because of the invasive techniques needed to
65 obtain bone marrow aspirates. PCR testing for typhoid is expensive and has a low diagnostic
66 sensitivity when used on peripheral blood samples.[16] Other available point-of-care (POC)
67 diagnostic tests include the Widal test,[17] TUBEX,[18] Typhidot,[19] Test-it Typhoid,[20] and the
68 Typhoid-Paratyphoid diagnostic assay (TPTest). However, these tests all have significant drawbacks
69 that limit their clinical use.

70

71 A Cochrane review of the accuracy of the commercially available antibody-based rapid RDTs showed
72 moderate sensitivity and specificity for the TUBEX colorimetric test that detects anti-O:9 antibody
73 titres (78%, 87%), the Typhidot dot enzyme linked immunosorbent assay (ELISA) that measures IgG
74 and IgM antibodies against the outer membrane proteins of *S. Typhi* (84%, 79%) and the Test-it
75 Typhoid immunochromatographic lateral flow assay that detects IgM antibodies against *S. Typhi* O
76 antigen (69%, 90%).[21] The TPTest is a newer serological test that detects circulating IgA using
77 ELISA with a sensitivity and specificity of >95%.[22] But it takes 24-48 hrs hours to produce a result,
78 and requires blood culture equipment not widely available in resource-limited settings.[14,22] Due to
79 the limited sensitivity of all current typhoid POC tests they cannot be relied upon to guide treatment
80 prescribing.

81

82 If developed and implemented effectively, an accurate typhoid RDT could reduce morbidity and
83 mortality through faster diagnosis. Further, it could help to reduce the overuse of antibiotics that
84 contributes to the emergence and spread of multidrug resistant strains of *S. Typhi* and other bacteria.
85 In recent years, novel approaches have been described to develop typhoid diagnostic tests with
86 improved accuracy in resource-limited settings, including serological, molecular, metabolomic,
87 proteomic, and transcriptomic methods.[7] For example, a recent study has shown that IgA and IgM
88 against *S. Typhi* lipopolysaccharide (LPS) may be a specific marker of acute typhoid infection and is
89 a promising target for diagnostic test development.[23]

90

91 As the need for appropriate fever case management becomes more apparent,[24] the need for
92 improved typhoid diagnostics suitable for use in low-resource environments becomes more pressing.
93 Building on the recent momentum around improved typhoid surveillance[25] and advances in typhoid
94 detection,[1] this report describes the development of a target product profile (TPP) in an attempt to
95 define the diagnostic needs for this important pathogen. The TPP is intended to guide product
96 development and to ensure an optimized solution that meets the needs of endemic countries and

97 results in tangible improvements in patient management. In addition, the TPP aims to re-invigorate
98 the discussion of diagnostics as a crucial part of the global typhoid agenda. This report focuses on the
99 process of TPP development with an emphasis on key test characteristics and discussion points
100 identified by typhoid experts and experienced stakeholders.

101 **METHODS**

102

103 **Data gathering**

104 A structured review of relevant literature related to *Salmonella* Typhi diagnosis was performed to
105 develop a draft TPP with minimal and optimal desired characteristics for a next-generation typhoid
106 diagnostic test. The test characteristics chosen for the TPP were selected based on previous TPPs
107 published by the Foundation for Innovative New Diagnostics (FIND)[26,27], and include the scope,
108 target population, intended use, expected test performance, as well as operational and financial
109 parameters (Table 1). Each desired test characteristic was classified as either a minimum requirement
110 that a test must meet to be useful for healthcare providers treating patients in resource-limited settings,
111 or an optimum threshold that would make the test highly desirable for both healthcare providers and
112 patients. The Ovid Medline database was accessed on June 21, 2018 using the Medical Subject
113 Heading (MeSH) “Typhoid fever” and the subheading “Diagnosis”. Results were restricted to English
114 language articles published in the previous 10 years. Titles and abstracts of retrieved articles were
115 scanned for relevance, with articles of interest thoroughly reviewed by RM for content relevant to the
116 TPP. Additional documents were identified by searching for “typhoid” on the websites of the
117 Cochrane library, WHO, and FIND, and by screening references and studies that cited articles
118 selected in the initial search. Expert stakeholders to be contacted for the Delphi survey were identified
119 as part of the literature review.

120

121 **Delphi survey**

122 Stakeholders were contacted for input on the draft TPP using a Delphi survey. Stakeholders included
123 specialists in clinical medicine (n = 14), laboratory medicine (n = 2), microbiology (n = 6),
124 diagnostics (n = 11) and public health and global health. An online survey (supplementary table 1)
125 was used and respondents were asked to rate their agreement with each of the TPP characteristics
126 using a Likert scale (1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = mostly
127 agree, 5 = fully agree). A consensus agreement was defined as $\geq 75\%$ of respondents who either
128 mostly or fully agreed with a TPP characteristic. Results from the first round of the survey (Oct/2018)
129 were used to refine the TPP, and a second draft of the TPP was distributed (Nov/2018) to all initial
130 participants as well as two additional stakeholders identified after the first round of the survey was
131 completed.

132

133

134

135

136

137

138

139 **Table 1: Typhoid target product profile parameters**

Category	Test characteristic
Scope of test	Goal Target population Target user Target level of health system
Test performance	Sample type Sample collection Sample volume/ sample transfer device Additional sample preparation Ease of use Hands on time Time to result Read out of results In use stability Data output + connectivity Data interpretation Analyte type Multiplexing Analytical sensitivity/ Limit of detection (LoD) Diagnostic sensitivity Diagnostic specificity Reproducibility
Operational characteristics	Kit configuration Reagent preparation Operating conditions Transportation and storage stability Equipment (Instrumentation external to test) External maintenance Calibration Internal/ Process control Batch/Quality control Power requirements Water requirement Waste disposal Bio-safety Training requirements Cost per test

140

141 **RESULTS**

142 An Ovid Medline search using the MeSH “Typhoid fever” produced 10,698 results, with 1,558 results
143 for the subheading “Diagnosis”. Limiting search results to English language articles published after
144 January 1st, 2008, provided 298 articles that were screened for relevance. Additional documents were
145 included as outlined in the Methods and selected articles were thoroughly reviewed to develop a draft
146 typhoid TPP with minimum and optimum criteria for the test characteristics in Table 1.

147

148 Feedback on the draft TPP was obtained from key stakeholders through the first round of the Delphi
149 survey, with 40 stakeholders contacted and 19 (19/40, 48%) completed surveys received. Survey
150 respondents had experience working in low resource settings in Africa, the Americas, Europe, the
151 Eastern Mediterranean, South-East Asia and the Western Pacific region. Consensus agreement of
152 $\geq 75\%$ was achieved for 34/36 (94%) TPP criteria. TPP criteria that generated the most discussion in
153 the Delphi survey were related to the scope of the test including the goal, target population, level of
154 the health care system, diagnostic sensitivity and specificity, as well as cost. Based on feedback from
155 survey respondents, “multiplexing” was removed as a TPP characteristic, and the remaining minimum
156 and optimum TPP criteria were revised. For criteria that had achieved consensus agreement, revisions
157 were made if survey respondents provided compelling suggestions for improvement.

158

159 A second draft of the TPP was distributed to the 19 people who responded to the initial Delphi survey,
160 and two additional stakeholders identified after completion of the first round. A total of 12 completed
161 surveys were received from 13 stakeholders, including two who submitted a joint survey, with
162 consensus agreement achieved for 33/35 (94%) TPP characteristics. The two criteria that did not meet
163 the consensus threshold were the target level of the health system and diagnostic sensitivity, both of
164 which received 67% agreement. Survey respondent feedback was used to revise these two criteria,
165 and to make minor changes to four criteria that had $\geq 75\%$ agreement, before inclusion in the final
166 version of the TPP presented in Tables 2, 3 and 4.

167

168 **Scope of test**

169 Delphi survey feedback emphasized that a next-generation RDT for typhoid fever should not focus
170 solely on the diagnosis of *S. Typhi*. To reduce the empiric use of antibiotics that generates selective
171 pressure for AMR, a typhoid RDT would ideally be combined with diagnostics for malaria and other
172 causes of acute febrile illness as part of a case management algorithm (Table 2). Due to the similar
173 clinical presentation and the changing epidemiology of *S. Typhi* and *S. Paratyphi*, survey respondents
174 advised that a next-generation test for typhoid fever should be able to detect both *S. Typhi* and *S.*
175 *Paratyphi*.

176 The target population was identified based on published data from Africa and Asia.[25,28] Children
 177 aged two to 14 years bear the brunt of the global typhoid burden but there is substantial variability
 178 both within and between regions in terms of who is most affected. A recent study from Pakistan found
 179 higher rates of typhoid fever in adults than in children.[28] These data highlight the need for a typhoid
 180 RDT that can detect the disease in individuals of all ages, as confirmed by the Delphi survey.

181

182 When designing new diagnostic tests, the level of the healthcare system where a test will be deployed
 183 is an important consideration. Ghani, *et al.*, have identified five healthcare system levels, with
 184 different types of diagnostic or prognostic tools suitable for different levels.[29] Typhoid is most
 185 prevalent in LMIC with limited healthcare resources, and in these contexts the optimal typhoid test
 186 would not require sophisticated equipment and could be easily interpreted by non-laboratory
 187 personnel.[6,7] Respondents agreed that a test would optimally be usable at the lowest level of a
 188 healthcare system, which in many cases is a community health worker seeing patients in an informal
 189 environment. However, as the current gold standard of blood culture requires laboratory equipment,
 190 but has suboptimal sensitivity and specificity, some respondents felt it was acceptable for a typhoid
 191 RDT to require basic laboratory facilities, with a trained laboratory technician, providing it meets all
 192 other TPP criteria. Based on feedback from the initial round of the Delphi survey the minimum target
 193 level was adjusted upward to a higher level of the health care system, but consensus agreement was
 194 not achieved as some respondents felt strongly that the minimum requirement should be a test that can
 195 be used in informal settings at the lowest level of the healthcare system.

196

197 **Table 2. Typhoid target product profile characteristics: scope of the test**

Characteristic	Minimal requirement	Optimal requirement	References
Goal	Point-of-care test to improve patient management through diagnosis and treatment of infection with acute <i>Salmonella enterica</i> serovars Typhi or Paratyphi	Combine with diagnostics for malaria and other causes of acute febrile illness as part of a treatment algorithm	[8,30]
Target population	All individuals with undifferentiated acute fever		[15,25,28]
Target user	Laboratory technician	Healthcare worker	[7]
Target level of health system*	District hospital with basic laboratory facilities	Primary health posts and centres	[6,29]

198 * Consensus not reached among survey respondents.

199

200 Test performance

201 Blood culture is commonly used as the reference standard for typhoid diagnosis but requires
 202 sophisticated equipment not readily available in LMIC where typhoid is endemic.[6] Typhoid blood
 203 cultures require a minimum of two to 10 mL of venous blood due to the low bacterial load in
 204 peripheral blood, and have poor sensitivity estimated at only 61% in a recent systematic review.[31]
 205 The most commonly used typhoid POC tests (Widal, Typhidot, Tubex, Test-It Typhoid, TPTest)

206 require between 5 μ L and 1 mL of blood, but have only moderate sensitivity and specificity.[21]
 207 Survey respondents agreed that an optimal next-generation typhoid RDT would use a capillary blood
 208 sample with a volume of ≤ 100 μ L, or a less invasive sample type, excluding urine and stool[12,26].
 209 However, survey respondents indicated that ≤ 1 mL of venous blood was an acceptable minimum
 210 requirement due to the current difficulty in accurately diagnosing typhoid fever (Table 3). The TPP
 211 allows for up to two sample processing steps as an RDT may require serum to be separated from
 212 whole blood, with at most five steps for the test of which no more than two should be timed,[26] and a
 213 total hands on time of less than five minutes. Based on a published expert consensus TPP for
 214 diagnostics for acute febrile illness, RDT performance ideally would entail three or fewer steps, of
 215 which at most one step is timed, with a total hands-on time of one minute or less.[26]

216

217 For a new typhoid diagnostic test to have the greatest impact on prescribing and clinical outcomes it
 218 would need to yields results in less than a few hours.[32] There was consensus agreement that the
 219 optimum requirement would make results available within 15 minutes to coincide with the average
 220 development time of other point-of-care diagnostics commonly used in LMIC environments (for
 221 example, malaria antigen-detecting RDTs). A minimum requirement of results within two hours was
 222 agreed; this would be a significant improvement from the ≥ 48 hours required for blood culture, and
 223 two hours was deemed the longest time that outpatients could wait for test results, particularly in rural
 224 settings where patients may have to travel long distances to reach a health facility.[26]

225

226

227

Table 3: Test performance characteristics for a typhoid diagnostic target product profile

Characteristic	Minimum requirement	Optimum requirement	References
Sample type	Venous blood	Capillary blood or less invasive sample type (e.g. saliva), excluding stool and urine	[12,26]
Sample collection	Transfer and quantification device included in the test		Industry standard
Sample volume/ sample transfer device	≤ 1 mL venous blood	≤ 100 μ L capillary blood	[33]
Additional sample preparation	2 sample processing steps	None required	May need to separate serum from whole blood before applying to RDT
Ease of use	≤ 5 steps, of which ≤ 2 are timed	≤ 3 steps, of which ≤ 1 is timed	[6]
Total hands-on time	≤ 5 minutes	≤ 1 minute	[7,26]
Time to result	≤ 2 hours	≤ 15 minutes	[26,32]
Read out of results	Binary results		[6]
In use stability	Results stable ≥ 15 minutes	Results stable ≥ 1 hour	[26]
Data output and connectivity	No wireless connectivity required	Wireless connectivity used to transfer data	[34]
Data interpretation	Readout easily interpretable by non-laboratory personnel	No data interpretation required	[7]
Analyte type	Any acceptable analyte, or combination of analytes, that can meet sensitivity and specificity thresholds		[7]
Analytical sensitivity/	Limit of detection should be such that it allows clinically		[7]

Limit of detection	relevant performance as defined below		
Diagnostic sensitivity*	≥90%	≥95%	[21,35–38]
Diagnostic specificity	≥95%	≥98%	[21,35–38]
Reproducibility	Kappa ≥0.9 between different operators and laboratories/locations		[39]

228 * Consensus not reached among survey respondents.

229

230 Researchers have proposed that an ideal typhoid diagnostic test would have a simple positive/negative
 231 read-out similar to a home pregnancy test,[6] with results easily interpretable by non-laboratory
 232 personnel.[7] The typhoid TPP therefore requires a binary read-out of results, with data that either do
 233 not require interpretation, or that are easily interpretable. No specific analyte or limit of detection is
 234 specified for the typhoid TPP, with any analyte or combination of analytes acceptable providing the
 235 test meets all other TPP requirements.

236

237 The minimum TPP requirement for diagnostic sensitivity is ≥90%, with an optimum sensitivity of
 238 ≥95%, based on modelling data and expert opinion.[21,35–38] Consensus agreement in the Delphi
 239 survey was not achieved for test sensitivity, which reflects the substantial variation in published
 240 expert opinions regarding the desirable accuracy for a typhoid RDT. However, survey respondents did
 241 agree on a minimum specificity of 95% and an optimum specificity of 98%.

242

243 **Operational characteristics**

244 Survey respondents agreed on operational characteristics of the typhoid TPP (Table 4). Typhoid
 245 diagnostic test kits ideally should consist of individually packaged tests with individual reagents (if
 246 required) and a user manual in local languages, based on TPP characteristics for other POC tests in
 247 regions where typhoid is endemic.[26,40,41] Up to one reagent preparation step is acceptable, to
 248 allow for reconstitution of a powdered reagent. The test should not require a cold chain, with
 249 operating conditions that reflect the high temperatures and humidity that are present in many regions
 250 in Africa and Asia where typhoid is prevalent.

251

252 **Table 4: Consensus operational characteristics for the typhoid target product profile**

Characteristic	Minimum requirement	Optimum requirement	References
Kit configuration	Package of single kits sharing reagents (if required) and user manual. Instructions in English, French, Spanish and Portuguese.	Package of single kits with individual reagents (if required) sharing user manual. Instructions in local languages.	[26,40]
Reagent preparation	One reagent preparation step	None required	[26,41]
Operating conditions	- between 5 and 40°C - ≤90% relative humidity	- between 5 and 45°C - ≤90% relative humidity	[40]
Transportation and storage stability	≥ 12 months at ≤35°C and ≤70% relative humidity, no cold chain needed, ability to withstand transport stress (≤3 days at 60°C)	≥ 24 months at ≤45°C and ≤90% relative humidity, no cold chain needed, ability to withstand transport stress (≤3 days at 60°C)	[40]
Equipment	Small, portable or handheld, battery-	No equipment	[6,7]

(Instrumentation external to test)	operated instrument		
External maintenance	Minimal maintenance, simple to perform by non-laboratory personnel	No maintenance	[26]
Calibration	≤1 annual calibration, ideally auto-calibration by operator or remotely	No calibration	[26]
Internal/Process control	Included in each assay		Industry standard
Batch/Quality control	Positive and negative controls included in each kit		Industry standard
Power requirements	Battery or solar powered	No power needed	[26]
Water requirement	No external water required		[26]
Waste disposal	Biohazard waste, sharps disposal	No toxic waste requiring special disposal	[42]
Bio-safety	Basic biosafety level 1, WHO Class B In-vitro diagnostic (moderate individual and low public health risk)	Basic biosafety level 1, WHO Class A In-vitro diagnostic (low individual and low public health risk).	[42,43]
Training requirements	≤ 0.5 days for lab technician	≤ 0.5 days for experienced health worker	[6,7,21]
Cost per test	End-user cost <\$3.00 USD	End-user cost <\$1.00 USD	[7,26]

253

254 Currently most typhoid treatments are provided in outpatient settings, including informal medical
 255 shops, so an ideal POC test would not require any sophisticated equipment or a formal laboratory
 256 infrastructure.[7] A small, portable or handheld battery-operated instrument is acceptable,[44] but
 257 ideally no equipment would be required. To be truly transformative, a typhoid POC test needs to be
 258 useable in settings without a reliable power or water supply. If power is required, then it should be
 259 provided by a combination of rechargeable batteries and solar power.

260

261 Empiric treatment of suspected typhoid cases is common, typically using relatively inexpensive
 262 antibiotics.[7] To reduce the overuse of empiric antibiotics, the end-user cost for a typhoid POC test
 263 was set at <\$3.00 USD (minimum requirement) or <\$1.00 USD (optimum requirement) to reflect the
 264 cost of empiric antibiotics in endemic regions.[7] Delphi survey feedback indicated that the highest
 265 cost to the end-user in Africa should be equivalent to one US dollar.

266

267 **DISCUSSION**

268 Typhoid diagnostic tests currently lack the sensitivity and specificity required for an accurate
269 diagnosis at the point of care, resulting in the overuse of antibiotics through empiric treatment. The
270 WHO has developed a list of characteristics that make a test suitable for the resource-limited settings
271 where typhoid is prevalent: the ASSURED acronym stands for affordable, sensitive, specific, user-
272 friendly, rapid and robust, equipment-free, and delivered to those in need.[44] TPPs build upon these
273 criteria and increasingly are used in the global health community to guide development of diagnostic
274 tests and to inform donors about global health priorities.[26,40,41] This TPP outlines the minimum
275 and optimum desired characteristics for an improved typhoid RDT and is intended to accelerate
276 development of optimized diagnostics that meet the needs of users in endemic regions.

277

278 Antibiotic resistance is a growing threat to typhoid treatment, with strains of *S. Typhi* that are resistant
279 to three first-line agents now prevalent in parts of Asia and Africa.[8] The emergence of multi-drug
280 resistant strains that have acquired additional resistance to fluoroquinolones and third-generation
281 cephalosporins, known as extremely drug resistant *S. Typhi*, has left azithromycin and the costly
282 intravenous carbapenem drugs as the only antibiotic options for some patients.[8] There have been
283 sporadic case reports of azithromycin-resistant *S. Typhi*,[8] but if extremely drug resistant strains
284 acquire azithromycin resistance, carbapenems could be left as the only effective treatment. To prevent
285 the further spread of resistant *S. Typhi* it would be beneficial to conduct drug susceptibility testing for
286 individual patients before commencing antibiotic therapy. Drug susceptibility testing was not included
287 as a TPP requirement because it is not likely to be feasible in non-culture POC tests due to the
288 evolving nature of typhoid resistance[8] and may make interpretation of test results too complex for
289 users at the lowest healthcare level[29]. However, some Delphi survey respondents felt that for an
290 RDT ever to replace blood culture it must include susceptibility testing. An RDT for diagnosis
291 combined with epidemiological knowledge of the antibiotic sensitivity of strains, updated at intervals,
292 could be a compromise solution.

293

294 The 2017 Global Burden of Disease study estimated that *S. Paratyphi* affected 3.4 million people
295 annually, with 19.1 thousand deaths, compared to 10.9 million cases and 116.8 thousand deaths for *S.*
296 *Typhi*. [2,3] The higher morbidity and mortality of *S. Typhi* makes it a greater public health concern,
297 but the increasing prevalence of *S. Paratyphi* in certain regions makes it prudent for a next-generation
298 test to detect *S. Paratyphi* as well as *S. Typhi*. [5,30,45] Delphi survey feedback noted that not being
299 able to detect *S. Paratyphi* could undermine clinician confidence in a next-generation typhoid POC
300 test as *S. Typhi* and *S. Paratyphi* may cause indistinguishable clinical syndromes.[4] As drug-resistant
301 typhoid continues to spread, it may become necessary to differentiate between these two serovars
302 prior to starting therapy due to different antibiotic susceptibility profiles.[46]

303

304 The minimum diagnostic requirement for a typhoid RDT in this TPP was $\geq 90\%$ sensitivity and $\geq 95\%$
305 specificity, with an optimum threshold of $\geq 95\%$ sensitivity and $\geq 98\%$ specificity. Consensus
306 agreement was achieved in the Delphi survey for specificity but not sensitivity, reflecting the
307 substantial variability seen in the published literature with proposed targets ranging from 80-90% for
308 sensitivity and 90-98% for specificity.[21,36,37] The poor sensitivity of blood culture as a reference
309 standard for typhoid diagnosis makes it difficult to accurately assess the performance of novel
310 diagnostic tests.[47] A composite reference standard that combines multiple tests with high specificity
311 but suboptimal sensitivity has been proposed as a possible way to improve diagnostic accuracy.[7,47]
312 Various test combinations have been used as a composite reference standard for typhoid,[47] but
313 respondents in this Delphi exercise advised that the adoption of a standardized composite is required
314 before it can be included in a TPP. A standardized composite might include tests (bone marrow
315 culture, PCR, transcriptomics etc.) that contribute to a reference standard but are not suitable for use
316 in regular practice.

317

318 Typhoid fever is transmitted by the faeco-oral route in water and food contaminated by *S. Typhi* in
319 human faeces and so is endemic in low-resource environments that lack access to clean water and
320 adequate sanitation. While improvements in the infrastructure for water, sanitation and hygiene could
321 reduce or eliminate typhoid, these are costly long-term endeavors. The newly approved Typbar-TCV
322 vaccine may help to reduce the global burden of enteric fever caused by *S. Typhi*,[48] but an improved
323 diagnostic test is required to accurately estimate disease incidence and facilitate targeted vaccine
324 deployment. To have a meaningful impact on the overuse of antibiotics that has contributed to the
325 emergence of resistance in *S. Typhi* and other bacteria, an improved typhoid POC test needs to be
326 used as part of a treatment algorithm in conjunction with diagnostics for malaria and other causes of
327 acute febrile illness. The isolated use of a disease-specific diagnostic test for a febrile patient may help
328 focus treatment if positive, but a negative test may result in alternative empiric antibiotic therapy, as
329 seen for malaria.[24,49] Drug susceptibility testing for *S. Typhi*, performed at reference laboratories,
330 could inform local treatment algorithms based on regional antibiotic susceptibilities.[50]

331

332 This work provides the first comprehensive TPP for a next-generation POC test for typhoid fever. The
333 main limitations of this study were the lack of consensus agreement for all TPP characteristics, and
334 the relatively low response rate in the second round of the Delphi survey. The length of the survey
335 may have been a barrier to completion due to the amount of time required to provide feedback on all
336 35 TPP characteristics. Further discussion among the typhoid community is needed to settle on the
337 optimal target level of the health care system and the required diagnostic sensitivity. While this TPP is
338 a first step toward improved awareness of the typhoid diagnostic needs, it is crucial to keep the
339 conversation going and to engage global health funders, diagnostics developers, and national policy
340 makers in the discussion on how improved diagnostic tools and related innovations can be used to

341 improve surveillance data as well as support patient management decisions in the context of universal
342 health care.
343

344 **ACKNOWLEDGEMENTS**

345 We thank all the participants of the 2 rounds of Delphi surveys for their invaluable contribution to
346 shape the TPP and highlight open questions. We would further like to thank the UK aid from the
347 British people for supporting this work.

348 REFERENCES

- 349 1 MacFadden DR, Bogoch II, Andrews JR. Advances in diagnosis, treatment, and prevention of
350 invasive Salmonella infections. *Curr Opin Infect Dis* 2016;**29**:453–8.
351 doi:10.1097/QCO.0000000000000302
- 352 2 GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and
353 national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for
354 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of
355 Disease Study 2017. *Lancet* 2018;:1789–858. doi:10.1016/S0140-6736(18)32279-7
- 356 3 Dicker D, Nguyen G, Abate D, *et al.* Global, regional, and national age-sex-specific mortality
357 and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study
358 2017. *Lancet* 2018;**392**:1684–735. doi:10.1016/S0140-6736(18)31891-9
- 359 4 Maskey AP, Day JN, Tuan PQ, *et al.* Salmonella enterica Serovar Paratyphi A and S. enterica
360 Serovar Typhi Cause Indistinguishable Clinical Syndromes in Kathmandu, Nepal. *Clin Infect
361 Dis* 2006;**42**:1247–53. doi:10.1086/503033
- 362 5 Bhutta ZA. Current concepts in the diagnosis and treatment of typhoid fever. *BMJ*
363 2006;**333**:78–82. doi:10.1136/bmj.333.7558.78
- 364 6 Parry CM, Wijedoru L, Arjyal A, *et al.* The utility of diagnostic tests for enteric fever in
365 endemic locations. *Expert Rev Anti Infect Ther* 2011;**9**:711–25. doi:10.1586/eri.11.47
- 366 7 Andrews JR, Ryan ET. Diagnostics for invasive Salmonella infections: Current challenges and
367 future directions. *Vaccine* 2015;**33**:C8–15. doi:10.1016/j.vaccine.2015.02.030
- 368 8 Klemm EJ, Shakoor S, Page AJ, *et al.* Emergence of an Extensively Drug-Resistant
369 Salmonella enterica Serovar Typhi Clone Harboring a Promiscuous Plasmid Encoding
370 Resistance to Fluoroquinolones and Third-Generation Cephalosporins. *MBio* 2018;**9**:e00105-
371 18. doi:10.1128/mBio.00105-18
- 372 9 Basnyat B. Typhoid versus typhus fever in post-earthquake Nepal. *Lancet Glob Heal*
373 2016;**4**:e516–7. doi:10.1016/S2214-109X(16)30094-8
- 374 10 Schroeder LF, Elbireer A, Jackson JB, *et al.* Laboratory Diagnostics Market in East Africa □:
375 A Survey of Test Types , Test Availability , and Test Prices in Kampala , Uganda. *PLoS Negl
376 Trop Dis* 2015;**10**:e0134578. doi:10.1371/journal.pone.0134578
- 377 11 Raffatellu M, Wilson RP, Winter SE, *et al.* Clinical pathogenesis of typhoid fever. *J Infect Dev
378 Ctries* 2008;**2**:260–6. doi:10.3855/jidc.219
- 379 12 Baker S, Favorov M, Dougan G. Searching for the elusive typhoid diagnostic. *BMC Infect Dis*
380 2010;**10**:45. doi:10.1186/1471-2334-10-45
- 381 13 Wain J, Song Diep T, Anh VH, *et al.* Quantitation of Bacteria in Blood of Typhoid Fever
382 Patients and Relationship between Counts and Clinical Features, Transmissibility, and
383 Antibiotic Resistance Downloaded from. *J Clin Microbiol* 1998;**36**:1683–7.
- 384 14 Khanam F, Sheikh A, Sayeed MA, *et al.* Evaluation of a Typhoid/Paratyphoid Diagnostic
385 Assay (TPTest) Detecting Anti-Salmonella IgA in Secretions of Peripheral Blood
386 Lymphocytes in Patients in Dhaka, Bangladesh. *PLoS Negl Trop Dis* 2013;**7**:e2316.
387 doi:10.1371/journal.pntd.0002316
- 388 15 World Health Organization. Typhoid vaccines: WHO position paper - March 2018. Geneva:
389 2018. <http://www.who.int/wer>
- 390 16 Von Kalckreuth V, Konings F, Aaby P, *et al.* The Typhoid Fever Surveillance in Africa
391 Program (TSAP): Clinical, Diagnostic, and Epidemiological Methodologies. *Clin Infect Dis*
392 2016;**62**:S9–16. doi:10.1093/cid/civ693
- 393 17 Tulip Diagnostics. Tydal Widal Antigen Set.
394 http://www.tulipgroup.com/Tulip_New/html/pack_inserts/Tydal.pdf (accessed 20 Aug 2018).
- 395 18 IDL Biotech AB. TUBEX TF Rapid Typhoid Detection. [http://idlbiotech.com/wp-
396 content/uploads/2018/08/IDL_TUBEX_folder-1511-web.pdf](http://idlbiotech.com/wp-content/uploads/2018/08/IDL_TUBEX_folder-1511-web.pdf) (accessed 16 Aug 2018).
- 397 19 Reszon Diagnostics. Typhidot Rapid IgG/IgM (Combo) Version2. 2014;**TF-
398 RD0202**. [https://www.reszonics.com/wp-content/uploads/2017/04/Reszon-IFU-TYPHIDOT-
399 Rapid-IgG_IgM-combo-2014-04.pdf](https://www.reszonics.com/wp-content/uploads/2017/04/Reszon-IFU-TYPHIDOT-Rapid-IgG_IgM-combo-2014-04.pdf) (accessed 16 Aug 2018).
- 400 20 LifeAssay Diagnostics. Test-it™ Typhoid IgM Lateral Flow Assay.
401 2016. <https://www.viaglobalhealth.com/wp-content/uploads/2016/03/Test-it-Typhoid->

- 402 Instructions.pdf (accessed 16 Aug 2018).
- 403 21 Wijedoru L, Mallett S, Parry C. Rapid diagnostic tests for typhoid and paratyphoid (enteric)
404 fever. *Cochrane Database Syst Rev* 2017;:Issue 5. Art. No.: CD008892.
405 doi:10.1002/14651858.CD008892.pub2
- 406 22 Islam K, Sayeed A, Hossen E, *et al.* Comparison of the Performance of the TPTest, Tubex,
407 Typhidot and Widal Immunodiagnostic Assays and Blood Cultures in Detecting Patients with
408 Typhoid Fever in Bangladesh, Including Using a Bayesian Latent Class Modeling Approach.
409 *PLoS Negl Trop Dis* 2016;**10**:e0004558. doi:10.1371/journal.pntd.0004558
- 410 23 Felgner J, Jain A, Nakajima R, *et al.* Development of ELISAs for diagnosis of acute typhoid
411 fever in Nigerian children. *PLoS Negl Trop Dis* 2017;**11**:e0005679.
412 doi:10.1371/journal.pntd.0005679
- 413 24 Bruxvoort KJ, Leurent B, Chandler CIR, *et al.* The Impact of Introducing Malaria Rapid
414 Diagnostic Tests on Fever Case Management: A Synthesis of Ten Studies from the ACT
415 Consortium. *Am J Trop Med Hyg* 2017;**97**:1170–9. doi:10.4269/ajtmh.16-0955
- 416 25 Marks F, von Kalckreuth V, Aaby P, *et al.* Incidence of invasive salmonella disease in sub-
417 Saharan Africa: a multicentre population-based surveillance study. 2017. doi:10.1016/S2214-
418 109X(17)30022-0
- 419 26 Dittrich S, Tadesse BT, Moussy F, *et al.* Target product profile for a diagnostic assay to
420 differentiate between bacterial and non-bacterial infections and reduce antimicrobial overuse
421 in resource-limited settings: An expert consensus. *PLoS One* 2016;**11**:1–12.
422 doi:10.1371/journal.pone.0161721
- 423 27 Denkinger CM, Dolinger D, Schito M, *et al.* Target product profile of a molecular drug-
424 susceptibility test for use in microscopy centers. *J Infect Dis* 2015;**211**:S39–49.
425 doi:10.1093/infdis/jiu682
- 426 28 Das JK, Hasan R, Zafar A, *et al.* Trends, Associations, and Antimicrobial Resistance of
427 Salmonella Typhi and Paratyphi in Pakistan. *Am J Trop Med Hyg* 2018;**99**:1–7.
428 doi:10.4269/ajtmh.18-0145
- 429 29 Ghani AC, Burgess DH, Reynolds A, *et al.* Expanding the role of diagnostic and prognostic
430 tools for infectious diseases in resource-poor settings. *Nature* 2015;**528**:S50–2.
431 doi:10.1038/nature16038
- 432 30 Radhakrishnan A, Als D, Mintz ED, *et al.* Introductory Article on Global Burden and
433 Epidemiology of Typhoid Fever. *Am J Trop Med Hyg* 2018;**99**:1–6. doi:10.4269/ajtmh.18-
434 0032
- 435 31 Mogasale V, Ramani E, Mogasale V V, *et al.* What proportion of Salmonella Typhi cases are
436 detected by blood culture? A systematic literature review. *Ann Clin Microbiol Antimicrob*
437 2016;**15**:32. doi:10.1186/s12941-016-0147-z
- 438 32 Obaro SK, Iroh Tam P-Y, Mintz ED, *et al.* The unrecognized burden of typhoid fever. *Expert*
439 *Rev Vaccines* 2017;**16**:249–60. doi:10.1080/14760584.2017.1255553
- 440 33 Duncan Steele A, Hay Burgess DC, Diaz Z, *et al.* Challenges and Opportunities for Typhoid
441 Fever Control: A Call for Coordinated Action. *Clin Infect Dis* 2016;**62**:S4–8.
442 doi:10.1093/cid/civ976
- 443 34 Shao AF, Rambaud-Althaus C, Samaka J, *et al.* New Algorithm for Managing Childhood
444 Illness Using Mobile Technology (ALMANACH): A Controlled Non-Inferiority Study on
445 Clinical Outcome and Antibiotic Use in Tanzania. *PLoS One* 2015;**10**:e0132316.
446 doi:10.1371/journal.pone.0132316
- 447 35 Thriemer K, Ley B, Menten J, *et al.* A Systematic Review and Meta-Analysis of the
448 Performance of Two Point of Care Typhoid Fever Tests, Tubex TF and Typhidot, in Endemic
449 Countries. *PLoS One* 2013;**8**. doi:10.1371/journal.pone.0081263
- 450 36 Maude RR, de Jong HK, Wijedoru L, *et al.* The diagnostic accuracy of three rapid diagnostic
451 tests for typhoid fever at Chittagong Medical College Hospital, Chittagong, Bangladesh. *Trop*
452 *Med Int Heal* 2015;**20**:1376–84. doi:10.1111/tmi.12559
- 453 37 Andrews JR, Arora P, Bogoch II, *et al.* Understanding the potential value of new diagnostics
454 for enteric fever □: insights from decision analytic modeling. *Am J Trop Med Hyg* 2017;**97**:617
455 (A: 1980). doi:10.4269/ajtmh.abstract2017
- 456 38 World Health Organization Communicable Disease Surveillance and Response Vaccines and

- 457 Biologicals. Background document: The diagnosis, treatment and prevention of typhoid fever.
458 Geneva: 2003. <http://www.who.int/rpc/TFGuideWHO.pdf>
- 459 39 Kim J-Y, Goo JS-Y, Na Y-K, *et al.* Comparison of Rapid Diagnostic Tests for the Detection of
460 *Plasmodium vivax* Malaria in South Korea. *PLoS One* 2013;**8**:64353.
461 doi:10.1371/journal.pone.0064353
- 462 40 Ding XC, Ade MP, Baird JK, *et al.* Defining the next generation of *Plasmodium vivax*
463 diagnostic tests for control and elimination: Target product profiles. *PLoS Negl Trop Dis*
464 2017;**11**:1–15. doi:10.1371/journal.pntd.0005516
- 465 41 Chua AC, Cunningham J, Moussy F, *et al.* The Case for Improved Diagnostic Tools to Control
466 Ebola Virus Disease in West Africa and How to Get There. *PLoS Negl Trop Dis*
467 2015;**9**:e0003734. doi:10.1371/journal.pntd.0003734
- 468 42 World Health Organization. Laboratory biosafety manual - Third edition. Geneva: 2004.
469 <http://www.who.int/csr/resources/publications/biosafety/Biosafety7.pdf?ua=1>
- 470 43 World Health Organization. Risk Based Classification of Diagnostics for WHO
471 Prequalification. 2014.
472 [http://www.who.int/diagnostics_laboratory/evaluations/140513_who_risk_based_classification](http://www.who.int/diagnostics_laboratory/evaluations/140513_who_risk_based_classification_of_ivds_for_pq_buffet.pdf)
473 [_of_ivds_for_pq_buffet.pdf](http://www.who.int/diagnostics_laboratory/evaluations/140513_who_risk_based_classification_of_ivds_for_pq_buffet.pdf) (accessed 1 Aug 2018).
- 474 44 Urdea M, Penny LA, Olmsted SS, *et al.* Requirements for high impact diagnostics in the
475 developing world. *Nature* 2006;**444**:73–9. doi:10.1038/nature05448
- 476 45 Darton TC, Blohmke CJ, Pollard AJ. Typhoid epidemiology, diagnostics and the human
477 challenge model. *Curr Opin Gastroenterol* 2014;**30**:7–17.
478 doi:10.1097/MOG.0000000000000021
- 479 46 McKinnon LR, Karim QA. Host-pathogen Interactions: Honing in on enteric fever. *Elife*
480 2014;**3**:e03545. doi:10.7554/eLife.03545
- 481 47 Storey HL, Huang Y, Crudder C, *et al.* A Meta-Analysis of Typhoid Diagnostic Accuracy
482 Studies: A Recommendation to Adopt a Standardized Composite Reference. *PLoS One*
483 2015;**10**:e0142364. doi:10.1371/journal.pone.0142364
- 484 48 Neuzil KM, Pollard AJ, Marfin AA. Introduction of Typhoid Conjugate Vaccines in Africa
485 and Asia. *Clin Infect Dis* 2019;**68**:S27–30. doi:10.1093/cid/ciy878
- 486 49 Hopkins H, Bruxvoort KJ, Cairns ME, *et al.* Impact of introduction of rapid diagnostic tests
487 for malaria on antibiotic prescribing: analysis of observational and randomised studies in
488 public and private healthcare settings. *BMJ* 2017;**356**:1054. doi:10.1136/bmj.j1054
- 489 50 Parry CM, Ribeiro I, Waila K, *et al.* Multidrug resistant enteric fever in South Asia: unmet
490 medical needs and opportunities. *BMJ* 2019;**364**:k5322. doi:10.1136/bmj.k5322
491